AstraZeneca has released findings from two Phase III studies, reporting outcomes for Ultomiris in thrombotic microangiopathy following HSCT-TMA and Sone-Ve in advanced gastric and GEJ cancers.

The post AstraZeneca reports Phase III results for Ultomiris and Sone-Ve appeared first on Clinical Trials Arena.